HBRS includes the following programs:
MD/PhD program Molecular Medicine (Speaker: Prof. Dr. Reinhold E.Schmidt; since 2000)
PhD program Infection Biology /DEWIN (Speaker: Prof. Dr. Reinhold Förster; since 2003)
PhD program Regenerative Sciences (Speaker: Prof. Dr. Ulrich Martin; since 2007)
PhD program Auditory Sciences (Speaker: Prof. Dr. Andrej Kral; since 2013)
PhD program Epidemiology (Speaker: Prof. Dr. Gerald Krause at HZI; since 2013)
IRTG 1273 (Speaker: Prof. Dr. Sebastian Sierbaum; since 2006)
ITN TECAS (Speaker: Dr. Sotirios Korossis; since 2013)
StrucMed (Speaker: Prof. Dr. Reinhold Förster; since 2005)
KlinStrucMed (Speaker: Prof. Dr. Heiner Wedemeyer; since 2015)
Master program Biomedicine (Speaker: Prof. Dr. Achim Gossler; since 2006)
Master program Biochemistry (Speaker: Prof. Dr. Matthias Gaestel; since 2007)
LISA (Speaker: Prof. Dr. Tim Sparwasser; since 2011)
In the following, only our three annual and oldest PhD programs are briefly introduced. For all other programs (PhD programs, Research Training Groups = IRTG, ITN, Master programs and StrucMed), please click on the link of the respective program on the scrollbar to the left.
Faculty: please see the individual programs
Core facilities of MHH
Hannover Medical School offers an international English PhD program in Molecular Medicine (MD/PhD program) in cooperation with the Leibniz Universität Hannover, the University of Veterinary Medicine Hannover, Foundation, the Helmholtz Center for Infection Research (HZI), Braunschweig (including the TwinCore institute in Hannover) and the Fraunhofer Institute for Toxicology and Experimental Medicine. The program was supported by the international PhD-program (IPP) of the Deutsche Akademische Austauschdienst und Deutsche Forschungsgemeinschaft (DAAD/DFG) from 2002 to 2006, and is now supported through funds of the German Excellence Initiative (DFG/BMBF) and Niedersachsen Vorab (State Lower Saxony). The program was accreditated as the first German PhD program according to European standards (ECTS) in December 2003.
The MD/PhD program "Molecular Medicine" is part of the Hannover Biomedical Research School. The program aims for students of medicine, after finishing their MD studies and having gained at least 6 months molecular research experience, as well as for graduated students of life sciences, who have finished their master of science (or Bachelor of Honors with research experience), particularly in biology, biochemistry, biotechnology and molecular biology. The program selects 20 students/year. Start of the program is annually in October. Deadline for applications is April 1st.
The program can be finished with a PhD or Dr.rer.nat. (for life scientists) after 3-4 years. The aim is to achieve 1-2 first author papers in peer-reviewed (high impact) journals and to write a cumulative thesis.
There are excellent career perspectives. Of more than 100 Alumni students so far, about 90% stay in research in well-known institutes worldwide, about 15 are already in faculty positions (group leader, habilitation, professors).
All students work in individually supervised research projects. It is an international program with students from all over the world. Stipends or positions are available for every student. Language courses are offered. There are tutorials and methodological seminars in small groups. There are also many soft skill courses, excursions to industry as well as social/cultural activities.
The theoretical part of the program comprises of English seminars in small groups and respective tutorials on selective topics of cellular and molecular biology. In addition, seminars are offered to specific research topics of molecular medicine.
The training for students of medicine will deepen their background of biomedical sciences. Scientists will understand medical and pathogenetic interrelationships. In addition, there is training and supervision particularly within the selected research projects. The dissertation is supervised by a group of three excellent scientists. PhD students work independently on highly competitive and grant funded research projects. The results of this work will be presented and discussed in respective seminars, workshops and on international congresses.
Seminars, courses and research projects are offered in following areas:
"Cellbiology", "Genetics", "Immunology", "Infection Biology", "Molecular Pathology", "Toxicology", "Developmental Biology", "Biochemistry", "Hematology and Oncology", "Stem cell research", "Signal transduction" etc.
Due to historical reasons, the MD/PhD program "Molecular Medicine" is the broadest one. Most of the clinical and theoretical departments/institutes of MHH are therefore participating.
Prof. R.E. Schmidt
Dept. of Clinical Immunology
Center of Internal Medicine at the MHH
+49-511-532-6656 / 7
Dr. Susanne Kruse and Birgit Müller
Präsidialamt der MHH
office: building I4 (Forschungswerkstätten), level 1
Prof. Dr. Thomas Thum (Vice chairman)
Prof. Dr. G. Behrens
Prof. Dr. M. Gaestel
Prof. Dr. A. Schambach
Prof. Dr. D. Manstein
Dr. S. Weiss
Prof. Dr. A. Braun
Alexandra Ingendoh (year 2012)
Katharina Lobschat / Ronja Komoll (year 2013)
Natalie Weber (year 2014)
Claudia Schröder / Sven Giese (year 2015)
Starting in fall 2003, ZIB launched the international PhD Program Infection Biology. In 2010, a new PhD program with the title "Dynamics of Host Pathogen Interactions - DEWIN" is launched. The 3-year programs, with English as the teaching language, play a pivotal role in the training of young scientists in the field of infection biology. The objective of both programs is to investigate the complex interactions between host and pathogen as well as basic research with the combined tools of immunology, cell biology and molecular biology.
20 students from across the world are accepted each year after a rigorous selection procedure. The study program Infection Biology is supported by the Wilhelm-Hirte Foundation, by scholarships provided by Hannover Medical School and through Georg-Christoph-Lichtenberg scholarships and administrative positions by the Ministry of Science and Culture of Lower Saxony. DEWIN-students will be supported by Georg-Christoph-Lichtenberg scholarships. Since Fall 2004 the European Union has participated in sponsoring PhD students via the elite program "Miditrain" which is funded by the EU "Marie Curie Actions" program.
60 students enrolled in the PhD Program work on a three-year research project and attend seminars, congresses, as well as lab courses. Students are encouraged and supported by a network of supervisors and support teams and finish the program after the PhD examination at the end of the third year as highly qualified scientists.
All students enroled in the PhD programs Infection Biology and DEWIN automatically become part of two research schools: the Hannover Biomedical Research School (HBRS) and the Helmholtz International Research School for Infection Biology (HIRSIB).
Prof. Dr. Reinhold Förster
Institute for Immunology
Medizinische Hochschule Hannover
Dr. Sabine Johann and
ZIB at the Institute for Immunology
Medizinische Hochschule Hannover
Prof. Dr. Reinhold Förster
Dr. Günter Bernhardt
Prof. Dr. Susanne Häußler
Prof. Dr. Georg Herrler
Dr. Matthias Lochner
Prof. Dr. Thomas Pietschmann
Prof. Dr. Reinhold Schmidt
Prof. Dr. Thomas F. Schulz
Prof. Dr. Sebastian Suerbaum
Prof. Dr. Peter Valentin-Weigand
A novel PhD Program "Regenerative Sciences" started in October 2007. This programme is designed and implemented by the Cluster of Excellence "From Regenerative Biology to Reconstructive Therapy" REBIRTH. This PhD study course is designed for students with an M.Sc. or equivalent diploma in Medicine, Veterinary Medicine, Biology, Biochemistry, Biotechnology, Molecular Biology, Chemistry or Physics. Engineers (e.g. Bioengineering) are welcome to apply as well.
The PhD program “Regenerative sciences” involves the partners of REBIRTH.
The 3-years curriculum is interdisciplinary and covers the following subjects:
Developmental biology: Principles of vertebrate and non-vertebrate development, embryogenesis and foetal period (focus on inner organs); genetic and epigenetic principles of development; model organisms; transgenic models (gain of function and loss of function); tissue specific transgenesis.
Stem cell biology: stem cell definition and classification (embryonic, foetal, germ cells, adult); normal and malignant stem cells; signal biology of self-renewal and differentiation (focus on heart, lung, liver, blood); stem cell purification and culture; genetic modification of stem cells (transient, semipermanent, stable); homing, migration and engraftment.
Ageing and degeneration: telomere biology, oxidative stress, somatic mutations; physical stress; inflammation; cancer; genetic determinants of life expectancy in model organisms; stem cell biology in aged organisms.
Inflammation: acute and chronic inflammation; inflammation and organ repair; inflammatory signals and (stem) cell biology; fibrosis.
Tumour biology: mechanisms of tumourigenesis; oncogenes and tumour suppressor genes; complementary mutations; loss of heterozygosity; induction and promotion; genetic and epigenetic stability, tumour immunity.
Transplantation (focus on heart, lung, liver, blood): rationale and need; organ availability; strategies (autologous, allogeneic, xenogeneic); transplant immunology (host versus graft and graft versus host); prosthetics; supportive care.
Materials sciences: biomaterials in medicine; classes of materials; materials engineering and functionalisation; biocompatibility; integration.
Growth factors and their receptors: regulation of cell survival, migration and apoptosis by ligands; soluble versus membrane-bound principles; gradients; clinical use of growth factors.
Cell therapy: forms and applications; cell sources; cell purification and processing; cell modification (genetic, epigenetic, via DNA, RNA, proteins and chemicals).Tissue engineering: principles and practice; the interdisciplinary basis of tissue engineering; integrating materials sciences and cell biology; quality and quantity issues; process development.
Process development and Good Practice: The three forms of Good Practice: clinical (GCP), manufacturing (GMP) and laboratory (GLP); rules and regulations; standard operating procedures (design, conduct, documentation); quality control; audits and reporting; upscaling and tuning of processes.
Risk assessment: biodistribution; horizontal and vertical transmission; complications of regenerative agents; complications of cell therapy and tissue engineering; proactive pharmacovigilance; design of preclinical models.
Clinical trials: design and conduct, informed consent contents and language, insurance.Regulatory and industry interactions: from basic research over process development to clinical trials; integrative and proactive communication with regulatory boards and industry.
Societal relations and ethical issues: principles of research ethics; history of regenerative medicine; “therapeutic” and reproductive cloning; cultural differences; health and economy and further societal issues; dialogue with patient organisations and the public.
Practical courses: These will be organised by REBIRTH’s service units or other key laboratories.
Prof. Dr. U. Martin
Dr. Daniela Pelz